Our study describes findings from the clinical audit of HER2 expression in gastric cancer in North-East India centre, providing the first insight into the rate of HER2-positivity in gastric and gastroesophageal adenocarcinoma. This evidence concerns the gene ERBB2 and gastric cancer.